AUM Biosciences

AUM Biosciences is an invigorating Singapore-based biotech startup aimed at revolutionizing cancer treatment. Armed with a focus on precision oncology, the company was founded by Vishal Doshi in 2018 with an inspiring mission - addressing the unmet needs of cancer patients in Asia. AUM Biosciences aims to provide global access to innovative, effective, and affordable cancer treatment for all patient communities.

The startup operates by developing and licensing promising oncology drugs, with an emphasis on precision medicine and targeted therapeutics. AUM Biosciences has a diverse pipeline of novel therapeutic agents designed to disrupt the status quo in the treatment of a range of cancer types. The company prides itself on a patient-centric approach, spearheading industry collaborations to ensure that each drug developed is not only potent but also safe for patients.

AUM Biosciences has achieved tremendous success in a short period of time, demonstrating a strong momentum and propensity for growth. Notably, its lead compound AUM001, a first-in-class anti-cancer drug, is currently progressing through pre-clinical development. AUM Biosciences stands as a testament to Singapore's booming startup ecosystem, spotlighting the potential for exponential advancement in the pursuit of better healthcare outcomes.

Company Details